The invariant NKT cell subset in anti-viral defenses: a dark horse in anti-influenza immunity? (Q37762343)

22 August 2017

1 reference

title

The invariant NKT cell subset in anti-viral defenses: a dark horse in anti-influenza immunity? (English)

1 reference

22 August 2017

R R Kulkarni

1

1 reference

PubMed ID

20519638

22 August 2017

S M Haeryfar

series ordinal

2

1 reference

PubMed ID

20519638

22 August 2017

S Sharif

series ordinal

3

1 reference

22 August 2017

2 June 2010

1 reference

Journal of Leukocyte Biology

22 August 2017

1 reference

22 August 2017

88

1 reference

22 August 2017

4

1 reference

22 August 2017

635-643

1 reference

Development of Valpha4+ NK T cells in the early stages of embryogenesis

22 August 2017

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Harnessing invariant NKT cells in vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Hepatic NKT cells: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Cross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Toward an understanding of NKT cell biology: progress and paradoxes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Regulation of autoimmune disease by natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Natural killer T cells and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

V alpha14 i NKT cells are innate lymphocytes that participate in the immune response to diverse microbes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

CD1d antigen presentation: treats for NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Natural ligand of mouse CD1d1: cellular glycosylphosphatidylinositol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Lipid protein interactions: the assembly of CD1d1 with cellular phospholipids occurs in the endoplasmic reticulum

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Lysosomal glycosphingolipid recognition by NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Intracellular bacterial infection and invariant NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

NK T cells stimulated with a ligand for TLR2 at least partly contribute to liver injury caused by Escherichia coli infection in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Toll-like receptor 2 contributes to liver injury by Salmonella infection through Fas ligand expression on NKT cells in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Impairment of liver regeneration correlates with activated hepatic NKT cells in HBV transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Production of profibrotic cytokines by invariant NKT cells characterizes cirrhosis progression in chronic viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Recognition of microorganisms and activation of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Toll-like receptor control of the adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Invariant NKT cells amplify the innate immune response to lipopolysaccharide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Cutting edge: the mechanism of invariant NKT cell responses to viral danger signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

The unique role of natural killer T cells in the response to microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Viral danger signals control CD1d de novo synthesis and NKT cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

CD1c bypasses lysosomes to present a lipopeptide antigen with 12 amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Viral evasion of antigen presentation: not just for peptides anymore

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Impaired cell surface expression of human CD1d by the formation of an HIV-1 Nef/CD1d complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Natural killer T cell activation inhibits hepatitis B virus replication in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Cutting edge: critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Cutting edge: Inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Alpha-galactosylceramide in chronic hepatitis B infection: results from a randomized placebo-controlled Phase I/II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Frequency and phenotype of circulating Valpha24/Vbeta11 double-positive natural killer T cells during hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Sustained response to interferon-alpha plus ribavirin therapy for chronic hepatitis C is closely associated with increased dynamism of intrahepatic natural killer and natural killer T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Cutting edge: Compartmentalization of Th1-like noninvariant CD1d-reactive T cells in hepatitis C virus-infected liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Impaired clearance of herpes simplex virus type 1 from mice lacking CD1d or NKT cells expressing the semivariant V alpha 14-J alpha 281 TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Interleukin-15 and natural killer and NKT cells play a critical role in innate protection against genital herpes simplex virus type 2 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Innate immune response to encephalomyocarditis virus infection mediated by CD1d

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

CD1d mediates T-cell-dependent resistance to secondary infection with encephalomyocarditis virus (EMCV) in vitro and immune response to EMCV infection in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Regulation of murine cerebral malaria pathogenesis by CD1d-restricted NKT cells and the natural killer complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Selective loss of natural killer T cells by apoptosis following infection with lymphocytic choriomeningitis virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Influenza and the challenge for immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Killer T cells in influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Invariant NKT cells sustain specific B cell responses and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Prolongation of cardiac allograft survival by rapamycin and the invariant natural killer T cell glycolipid agonist OCH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0410191

21 January 2018

Identifiers

DOI

10.1189/JLB.0410191

1 reference

22 August 2017

1 reference

PubMed ID

20519638